Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis

Affiliations

• ¹ Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA.
• ² Department of Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
• ³ Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
• ⁴ Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.
• ⁵ Department of Pharmacy, Stanford Healthcare, Stanford, CA, USA.
• ⁶ Department of Medicine, Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA.
• ⁷ Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: gmannis@stanford.edu.